IP Library Granted Patent US 9,512,211
Granted Patent B2
US 9,512,211 · App. 14/311,840 · Granted Dec 6, 2016

Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume

Inventors: Gilles Bernard Tremblay (La Prairie, CA); Mario Filion (Longueuil, CA); Traian Sulea (Kirkland, CA)
Assignee: Alethia Biotherapeutics Inc.
C07K16/18A61K31/337A61K39/39558A61K45/06A61K49/0004C07K16/30C07K2317/24C07K2317/33C07K2317/55C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,512,211
App. No.
14/311,840
Granted
Dec 6, 2016
Kind
B2
Abstract

Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.

Claims (14)

1. A method of reducing the growth of a cancer cell expressing clusterin or of reducing volume of a tumor comprising cells expressing or secreting clusterin, the method comprising administering an antibody or an antigen binding fragment thereof capable of specific binding to clusterin to a mammal in need thereof, wherein the antibody or antigen binding fragment thereof comprises:

a. a light chain variable region as set forth in SEQ ID NO.:8 and a heavy chain variable region as set forth in SEQ ID NO.:7;

b. a light chain variable region as set forth in SEQ ID NO.:8 and a heavy chain variable region as set forth in SEQ ID NO.:29 or;

c. a light chain variable region as set forth in SEQ ID NO.:25 and a heavy chain variable region as set forth in SEQ ID NO.:7.

2. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a light chain variable region as set forth in SEQ ID NO.:8 and a heavy chain variable region as set forth in SEQ ID NO.:7.

3. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a light chain as set forth in SEQ ID NO.:10 and a heavy chain as set forth in SEQ ID NO.:9.

4. The method of claim 1 , wherein the mammal in need receives chemotherapy.

5. A method of treating carcinoma, the method comprising administering an antibody or an antigen binding fragment thereof capable of specific binding to clusterin to a mammal in need, wherein said antibody or antigen binding fragment thereof comprises:

a. a light chain variable region as set forth in SEQ ID NO.:8 and a heavy chain variable region as set forth in SEQ ID NO.:7;

b. a light chain variable region as set forth in SEQ ID NO.:8 and a heavy chain variable region as set forth in SEQ ID NO.:29 or;

c. a light chain variable region as set forth in SEQ ID NO.:25 and a heavy chain variable region as set forth in SEQ ID NO.:7.

6. The method of claim 5 , wherein the antibody or antigen binding fragment thereof comprises a light chain variable region as set forth in SEQ ID NO.:8 and a heavy chain variable region as set forth in SEQ ID NO.:7.

7. The method of claim 5 , wherein the antibody or antigen binding fragment thereof comprises a light chain as set forth in SEQ ID NO.:10 and a heavy chain as set forth in SEQ ID NO.:9.

8. The method of claim 5 wherein the mammal in need receives chemotherapy.

Assignments (4)
CHANGE OF NAME Recorded Aug 25, 2025
From: ALETHIA BIOTHERAPEUTICS INC.
To: ALETHIA BIOTHERAPEUTICS ULC
Reel/Frame 072107/0559 →
LICENSE Recorded Mar 25, 2015
From: NATIONAL RESEARCH COUNCIL OF CANADA
To: ALETHIA BIOTHERAPEUTICS INC.
Reel/Frame 035251/0608 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2014
From: SULEA, TRAIAN
To: NATIONAL RESEARCH COUNCIL OF CANADA
Reel/Frame 033914/0059 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2014
From: TREMBLAY, GILLES BERNARD; FILION, MARIO
To: ALETHIA BIOTHERAPEUTICS INC.
Reel/Frame 033914/0137 →
Continuity (3)
Division 13502427
Provisional Application 61263865 · Nov 24, 2009
Related Publication 20140302020A1 · Oct 9, 2014